Jefferies downgraded Opko Health (OPK) to Hold from Buy with a price target of $1.60, down from $2. The firm, which is lowering Ngenla out-year estimates, says Opko’s drug pipeline has potential, but is still early with a need for clarity on catalysts.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OPK: